Treatment using Oxaliplatin and S-1 Adjuvant chemotherapy for Stage III gastric cancer trial
- Conditions
- Gastric cancer
- Registration Number
- JPRN-UMIN000025824
- Lead Sponsor
- Department of Surgery, Kochi Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 75
Not provided
1. Synchronous or metachronous malignant disease, or multicentric cancer. 2. Serious postoperative morbidity such as serious infection, anastomotic leakage, gastrointestinal bleeding and so on. 3. Serious concurrent disease such as intestinal palsy, small bowel obstraction, interstitial pneumonia, pulmonary fibrosis, uncontrolable diabetes mellitus, heart failure, renal failure, liver cirrhosis, hepatic failure, and so on. 4. Active infectious disease. 5. Positive of HBs antigen or HCV antibody. 6. Continuous treatment with steroids. 7. Serious diarrhea. 8. A medical history of serious allergy to any drug. 9. Ascites beyond the pelvic cavity or pleural effusion. 10. Brain metastasis. 11. Taking flucytosine or phenytoin. 12. Needs of taking warfarin potassium. 13. Sensory neuropathy caused by any drug. 14. A history of blood transfusion or administration of granulocyte-colony stimulating factor within 3 weeks before enrollment. 15. Women who are pregnant or hope to become pregnant during the study period. 16. Patients judged inappropriate for the study by their physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.